Navigation Links
Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
Date:10/6/2008

PRINCETON, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that Richard E.T. Smith, Ph.D., is joining the Company as Vice President of Investor Relations and Corporate Communications. Dr. Smith will be responsible for all investor relations functions and will report directly to Chief Financial Officer Kurt Leutzinger.

Most recently, Dr. Smith was a Vice President and Senior Biotechnology Analyst at JPMorgan Securities, and has been an analyst in the sector since 2000. Dr. Smith holds a Ph.D. from the University of Oxford with a focus in Virology, Immunology and Molecular Biology and has published research in medical journals including Virology.

"We are pleased to welcome Richard to Pharmasset," said Schaefer Price, CEO. "As a seasoned analyst with expertise in our areas of disease focus who has earned the trust of investors, he will continue to strengthen our relationship with our shareholders and the investment community."

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

CFO

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
2. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
3. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
4. Photos: Sentara Joins 4 U.S. Hospitals in International TARGIT Breast Cancer Trial
5. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
6. Vincent W. Renz Joins NewCardio as President
7. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
8. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
9. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
10. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
11. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 According to market ... Growth and Demand Forecast to 2022 - Industry ... Application (Drug Discovery and Development, Proteomics, Clinical Testing, ... Science and Biotechnology, Academic and Research Institute, Hospitals ... global mass spectrometry market was valued ...
(Date:5/23/2016)... , May 23, 2016 Non-invasive ... detection of multiple diseases; ,Technology to be presented at ... Yissum Research Development Company of the Hebrew University ... a research agreement with Aurum Ventures MKI, the technology investment ... of a new diagnostic approach for early detection of ...
(Date:5/23/2016)... FRANCISCO , May 23, 2016 ... to reach USD 5.0 billion by 2022, according to ... increasing generation of medical waste coupled with the lack ... industry is expected to drive the demand for reprocessed ... these devices as compared to that of the original ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... A newly released report reveals that improving life outcomes for boys and ... face-to-face interactions and online. In “Heard, Not Judged – Insights into the Talents, Realities ... mobile digital devices can be an effective tool to help boys and men of ...
(Date:5/24/2016)... ... ... Growing in popularity, more and more people continue to live their lives ... Whether someone chooses to cut gluten out of their life for personal health reasons ... their shelves with many different gluten-free products all year round. And they take another ...
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies International, ... to its board of directors. Otterstatter is co-founder, president and CEO of ... innovations that lead to broad-based healthcare solutions. , “Jon knows how to create ...
(Date:5/24/2016)... ... 24, 2016 , ... Tuesday, May 24, Women's Excellence in Wellness, powered by ... Living Essential Oils, taught by Patti Dolan, RYT, a Young Living Gold Member. ... is 6:30pm - 7:15pm followed by a small intro to the Oils that can ...
(Date:5/24/2016)... ... 24, 2016 , ... As reported by MassGeneral.org, on May 8 – 9, ... United States . The 64-year-old patient who received the transplant had undergone a partial ... only a natural appearance, but also urinary and sexual function for the patient who ...
Breaking Medicine News(10 mins):